Adaptin Bio, Inc.
APTN
$6.20
$0.000.00%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 24.14% | 210.00% | 187.28% | 1,334.39% | 682.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.53% | 169.24% | 68.45% | 98.21% | 183.78% |
| Operating Income | -34.53% | -169.24% | -68.45% | -98.21% | -183.78% |
| Income Before Tax | -90.03% | -59.66% | -51.28% | -85.77% | -77.70% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -90.03% | -59.66% | -51.28% | -85.77% | -77.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -90.03% | -59.66% | -51.28% | -85.77% | -77.70% |
| EBIT | -34.53% | -169.24% | -68.45% | -98.21% | -183.78% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -27.25% | 38.81% | 41.84% | 28.58% | 0.86% |
| Normalized Basic EPS | 17.45% | 20.88% | 41.83% | 28.59% | -52.68% |
| EPS Diluted | -27.25% | 38.58% | 41.31% | 28.54% | 0.86% |
| Normalized Diluted EPS | 17.45% | 20.88% | 41.83% | 28.59% | -52.68% |
| Average Basic Shares Outstanding | 49.34% | 161.01% | 160.18% | 160.14% | 79.29% |
| Average Diluted Shares Outstanding | 49.34% | 161.01% | 160.18% | 160.14% | 79.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |